Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.63 |
| ▸ | HTR2A | P28223 | 11/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6494772 | 0.98 | HTR2C (0.62) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL5413796 | 0.91 | HTR2C (0.60) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL6495715 | 0.90 | HTR2C (0.59) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL5428200 | 0.89 | HTR2C (0.62) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL5424435 | 0.88 | HTR2C (0.60) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL5739830 | 0.84 | HTR2C (0.80) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL5739283 | 0.84 | HTR2C (0.80) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL5740802 | 0.82 | HTR2C (0.80) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL3542992 | 0.81 | HTR2C (0.69) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL3539313 | 0.81 | HTR2C (0.69) | HTR2CHTR2AKDM4EALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | PFIZER | 2005-12-22 | — | — | US | claimed |
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | claimed |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | claimed |
| JP-2002543080-A | — | — | 2002-12-17 | — | — | JP | claimed |
| EP-1173440-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2000064899-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | TBXA2R, NPY5R, AZI2 | HTR2C 22/4885HTR2A 34/4885KDM4E 1036/4885 |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | HTR2C 24/4885HTR2A 43/4885KDM4E 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.